A recent Letter to the Editor defending the 340B drug discount program (Clinical Oncology News 2016;2[13]:2; http://bit.ly/?2mLzxFG) sidesteps the evidence showing it has become a pot of gold for America’s hospitals and desperately needs reform.
A Good Idea Run Amok
340B was created to help uninsured and indigent patients access needed medicines, but it has gone bad. A report by Avalere Health determined that just 24% of 340B hospitals provide 80% of all charity care (